| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2398 | 2015 |
| Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial CM Nutting, JP Morden, KJ Harrington, TG Urbano, SA Bhide, C Clark, ... The lancet oncology 12 (2), 127-136, 2011 | 1968 | 2011 |
| Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study GC Barnett, CE Coles, RM Elliott, C Baynes, C Luccarini, D Conroy, ... The lancet oncology 13 (1), 65-77, 2012 | 1836 | 2012 |
| Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial D Dearnaley, I Syndikus, H Mossop, V Khoo, A Birtle, D Bloomfield, ... The Lancet Oncology 17 (8), 1047-1060, 2016 | 1362 | 2016 |
| Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial RC Coombes, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman, ... The Lancet 369 (9561), 559-570, 2007 | 1119 | 2007 |
| Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer ND James, SA Hussain, E Hall, P Jenkins, J Tremlett, C Rawlings, ... New England Journal of Medicine 366 (16), 1477-1488, 2012 | 1076 | 2012 |
| Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors R Doll, R Peto, E Hall, K Wheatley, R Gray Bmj 309 (6959), 911-918, 1994 | 939 | 1994 |
| Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial J Mateo, N Porta, D Bianchini, U McGovern, T Elliott, R Jones, I Syndikus, ... The Lancet Oncology 21 (1), 162-174, 2020 | 629 | 2020 |
| Intermittent androgen suppression for rising PSA level after radiotherapy JM Crook, CJ O'Callaghan, G Duncan, DP Dearnaley, CS Higano, ... New England Journal of Medicine 367 (10), 895-903, 2012 | 598 | 2012 |
| Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup … RE Coleman, LM Banks, SI Girgis, LS Kilburn, E Vrdoljak, J Fox, ... The lancet oncology 8 (2), 119-127, 2007 | 512 | 2007 |
| Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised … DH Brand, AC Tree, P Ostler, H van der Voet, A Loblaw, W Chu, D Ford, ... The Lancet Oncology 20 (11), 1531-1543, 2019 | 498 | 2019 |
| Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin OM Martínez-Estrada, LA Lettice, A Essafi, JA Guadix, J Slight, V Velecela, ... Nature genetics 42 (1), 89-93, 2010 | 448 | 2010 |
| Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial A Birtle, M Johnson, J Chester, R Jones, D Dolling, RT Bryan, C Harris, ... The Lancet 395 (10232), 1268-1277, 2020 | 445 | 2020 |
| Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. M Pasquali, J Vela, R Kyle, T Leong, E Fritz, S Suciu, IP Palva, T Oivanen, ... Journal of Clinical Oncology 16 (12), 3832-3842, 1998 | 441 | 1998 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 417 | 2017 |
| Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial D Dearnaley, I Syndikus, G Sumo, M Bidmead, D Bloomfield, C Clark, ... The lancet oncology 13 (1), 43-54, 2012 | 372 | 2012 |
| Clinical development of new drug–radiotherapy combinations RA Sharma, R Plummer, JK Stock, TA Greenhalgh, O Ataman, S Kelly, ... Nature reviews Clinical oncology 13 (10), 627-642, 2016 | 316 | 2016 |
| Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects DP Dearnaley, E Hall, D Lawrence, RA Huddart, R Eeles, CM Nutting, ... British journal of cancer 92 (3), 488-498, 2005 | 308 | 2005 |
| Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA LM Secker‐Walker, HG Prentice, J Durrant, S Rchards, E Hall, G Harrison British journal of haematology 96 (3), 601-610, 1997 | 292 | 1997 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 273 | 2020 |
Robert HuddartInstitution of Cancer ResearchVahvistettu sähköpostiosoite verkkotunnuksessa icr.ac.uk
